NCT02456948 (Mino-TRD) is a Phase 2 clinical trial of Minocycline in Major Depressive Disorder, sponsored by Charite University, Berlin, Germany.

Who is sponsoring NCT02456948?

NCT02456948 is sponsored by Charite University, Berlin, Germany.

What drugs are being tested in NCT02456948?

Interventions in NCT02456948: Minocycline, Placebo.

What condition does NCT02456948 study?

NCT02456948 studies Major Depressive Disorder.

Is NCT02456948 still recruiting?

NCT02456948 is currently completed. Last updated 16 October 2020.

Last reviewed 2020-10-16 · How we verify

NCT02456948: Mino-TRD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Unipolar Major Depressive Disorder (MDD)

Completed Phase 2 Last updated 16 October 2020

What this trial tests

Phase 2 trial testing Minocycline in Major Depressive Disorder in 168 participants. Completed in 7 August 2020.

Timeline

1 January 2015

Primary endpoint
7 August 2020

7 August 2020

Quick facts

Lead sponsor	Charite University, Berlin, Germany
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	168
Start date	1 January 2015
Primary completion	7 August 2020
Estimated completion	7 August 2020
Sites	9 locations across Germany

Drugs / interventions tested

Minocycline (MINOCYCLINE) — full drug profile →
Placebo

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Charite University, Berlin, Germany

Who can join

Adults 18 to 75, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Response as per MADRS (Montgomery-Åsberg Depression Rating Scale)
Time frame: 6 weeks

Sponsor's own description

This study examines the antidepressant efficacy of minocycline as an adjunct to an antidepressant standard treatment (AD-ST), for patients with unipolar major depressive disorder (MDD).

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Hellmann-Regen J, Clemens V, Grözinger M, Kornhuber J, et al · · 2022 · cited 70× · PMID 36103181 · DOI 10.1001/jamanetworkopen.2022.30367
Novel drug developmental strategies for treatment-resistant depression.
Borbély É, Simon M, Fuchs E, Wiborg O, et al · · 2022 · cited 70× · PMID 34822719 · DOI 10.1111/bph.15753
Immune-based strategies for mood disorders: facts and challenges.
Colpo GD, Leboyer M, Dantzer R, Trivedi MH, et al · · 2018 · cited 69× · PMID 29179585 · DOI 10.1080/14737175.2018.1407242
Depression following a traumatic brain injury: uncovering cytokine dysregulation as a pathogenic mechanism.
Bodnar CN, Morganti JM, Bachstetter AD. · · 2018 · cited 55× · PMID 30136679 · DOI 10.4103/1673-5374.238604
Investigational drugs in recent clinical trials for treatment-resistant depression.
Garay RP, Zarate CA, Charpeaud T, Citrome L, et al · · 2017 · cited 50× · PMID 28092469 · DOI 10.1080/14737175.2017.1283217
Inflamed brain: Targeting immune changes and inflammation for treatment of depression.
Sakamoto S, Zhu X, Hasegawa Y, Karma S, et al · · 2021 · cited 37× · PMID 34227186 · DOI 10.1111/pcn.13286
Anti-inflammatory effects of minocycline are mediated by retinoid signaling.
Clemens V, Regen F, Le Bret N, Heuser I, et al · · 2018 · cited 20× · PMID 30241502 · DOI 10.1186/s12868-018-0460-x

Verify or expand the search:

Other trials of Minocycline

Trials testing the same drug.

NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07305896 — Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage · NA · not yet recruiting
NCT07068607 — Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradicatio · Phase 4 · recruiting
NCT06523764 — Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment · Phase 4 · active not recruiting
NCT06120140 — Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small · Phase 2 · recruiting

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Charite University, Berlin, Germany trials

Trials by the same sponsor.

NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02456948 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
Last refreshed: 16 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02456948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing